FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955334881> ?p ?o ?g. }

• W2955334881 endingPage "iv89" @default.
• W2955334881 startingPage "iv89" @default.
• W2955334881 abstract "Introduction: Locally advanced pancreatic adenocarcinomas (PANCAN) are treated using multi-agent systemic chemotherapy with variable rates of resectability. Stereotactic Body Radiotherapy (SBRT) is utilized to improve tumor resectability or for sustained local tumor control. However, the safety and tolerance of combining FOLFIRINOX or Gemcitabine-nabPaclitaxel (Gem-Abr) with SBRT is unknown. This study aimed to evaluate the safety and tolerability of pancreatic SBRT following FOLFIRINOX or Gemcitabine-nabPaclitaxel chemotherapy in unresectable PANCAN. Methods: Between 2015 and 2018, 30 patients with locally advanced PANCAN were treated with systemic chemotherapy and SBRT. Patients with borderline or unresectable tumors were eligible, as determined based on findings on pancreatic protocol-CT, by a multidisciplinary team including pancreatico-biliary surgeons. Patients with performance status ECOG 0-2 received FOLFIRINOX (n = 19), Gemcitabine-nabPaclitaxel (n = 10) or Gemcitabine alone (n = 1) for at least two months prior to SBRT. All patients proceeded to SBRT regardless of operability status at the end of chemotherapy as long as there was no progression by RECIST 1.1 criteria. SBRT dose was 33 Gy in 5 fractions in 25 patients, while in 4 patients SBRT dose was allowed escalate up to 40 Gy in 5 fractions, while staying within the tolerance limits of normal structures. All patients received SBRT utilizing a dynamic arc technique, with kV image guidance and appropriate respiratory motion correction. Patients deemed operable on CT evaluation at 4 weeks from the end of SBRT proceeded to Whipple resection. Results: Seventeen males and 13 females with median age of 66 years (40 to 83) were treated. All patients completed planned chemotherapy with minimal interruptions. At the end of chemotherapy 9 patients (31%) were down-staged to operable status. SBRT was completed in all patients without interruptions. All SBRT toxicities were graded < 2, except one instance of Grade 3 nausea in a patient who received 33 Gy. Nine patients (31%) were taken for Whipple resection and 8 successfully underwent R0 resection. One patient died postoperatively due to sepsis. 20 patients (69%) who did not proceed to surgery received additional chemotherapy and were followed up until death. The median follow-up for the study cohort is 6.2 months. Nine patients (30%) have died, due to distant or loco-regional progression. Six patients showed disease progression at the primary site of tumor, of which 2 patients documented progression prior to SBRT. The overall loco-regional control rate was 79%. The median progression-free survival and overall survival of the study cohort were 9.43 and 11.7 months respectively. Conclusion: Neoadjuvant chemotherapy using FOLFIRINOX or Gem-Abr followed by SBRT is a safe approach to manage locally advanced PANCAN. SBRT doses up to 40 Gy in 5 fractions are associated with minimal toxicities provided tolerances of normal tissues are respected." @default.
• W2955334881 created "2019-07-12" @default.
• W2955334881 creator A5000425500 @default.
• W2955334881 creator A5000827226 @default.
• W2955334881 creator A5001717156 @default.
• W2955334881 creator A5006538210 @default.
• W2955334881 creator A5021909013 @default.
• W2955334881 creator A5024199124 @default.
• W2955334881 creator A5038817160 @default.
• W2955334881 creator A5039857530 @default.
• W2955334881 creator A5042094731 @default.
• W2955334881 creator A5051180078 @default.
• W2955334881 creator A5051654669 @default.
• W2955334881 creator A5056381312 @default.
• W2955334881 creator A5071825465 @default.
• W2955334881 creator A5072799975 @default.
• W2955334881 creator A5089480050 @default.
• W2955334881 date "2019-07-01" @default.
• W2955334881 modified "2023-09-25" @default.
• W2955334881 title "Stereotactic body radiotherapy in locally advanced pancreatic adenocarcinoma: A single institution experience" @default.
• W2955334881 doi "https://doi.org/10.1093/annonc/mdz155.323" @default.
• W2955334881 hasPublicationYear "2019" @default.
• W2955334881 type Work @default.
• W2955334881 sameAs 2955334881 @default.
• W2955334881 citedByCount "2" @default.
• W2955334881 countsByYear W29553348812021 @default.
• W2955334881 countsByYear W29553348812022 @default.
• W2955334881 crossrefType "journal-article" @default.
• W2955334881 hasAuthorship W2955334881A5000425500 @default.
• W2955334881 hasAuthorship W2955334881A5000827226 @default.
• W2955334881 hasAuthorship W2955334881A5001717156 @default.
• W2955334881 hasAuthorship W2955334881A5006538210 @default.
• W2955334881 hasAuthorship W2955334881A5021909013 @default.
• W2955334881 hasAuthorship W2955334881A5024199124 @default.
• W2955334881 hasAuthorship W2955334881A5038817160 @default.
• W2955334881 hasAuthorship W2955334881A5039857530 @default.
• W2955334881 hasAuthorship W2955334881A5042094731 @default.
• W2955334881 hasAuthorship W2955334881A5051180078 @default.
• W2955334881 hasAuthorship W2955334881A5051654669 @default.
• W2955334881 hasAuthorship W2955334881A5056381312 @default.
• W2955334881 hasAuthorship W2955334881A5071825465 @default.
• W2955334881 hasAuthorship W2955334881A5072799975 @default.
• W2955334881 hasAuthorship W2955334881A5089480050 @default.
• W2955334881 hasBestOaLocation W29553348811 @default.
• W2955334881 hasConcept C121608353 @default.
• W2955334881 hasConcept C126322002 @default.
• W2955334881 hasConcept C126838900 @default.
• W2955334881 hasConcept C197934379 @default.
• W2955334881 hasConcept C2776694085 @default.
• W2955334881 hasConcept C2777148230 @default.
• W2955334881 hasConcept C2778375690 @default.
• W2955334881 hasConcept C2778822529 @default.
• W2955334881 hasConcept C2779984678 @default.
• W2955334881 hasConcept C2780258809 @default.
• W2955334881 hasConcept C2780962732 @default.
• W2955334881 hasConcept C2781182431 @default.
• W2955334881 hasConcept C526805850 @default.
• W2955334881 hasConcept C71924100 @default.
• W2955334881 hasConceptScore W2955334881C121608353 @default.
• W2955334881 hasConceptScore W2955334881C126322002 @default.
• W2955334881 hasConceptScore W2955334881C126838900 @default.
• W2955334881 hasConceptScore W2955334881C197934379 @default.
• W2955334881 hasConceptScore W2955334881C2776694085 @default.
• W2955334881 hasConceptScore W2955334881C2777148230 @default.
• W2955334881 hasConceptScore W2955334881C2778375690 @default.
• W2955334881 hasConceptScore W2955334881C2778822529 @default.
• W2955334881 hasConceptScore W2955334881C2779984678 @default.
• W2955334881 hasConceptScore W2955334881C2780258809 @default.
• W2955334881 hasConceptScore W2955334881C2780962732 @default.
• W2955334881 hasConceptScore W2955334881C2781182431 @default.
• W2955334881 hasConceptScore W2955334881C526805850 @default.
• W2955334881 hasConceptScore W2955334881C71924100 @default.
• W2955334881 hasLocation W29553348811 @default.
• W2955334881 hasOpenAccess W2955334881 @default.
• W2955334881 hasPrimaryLocation W29553348811 @default.
• W2955334881 hasRelatedWork W1148461151 @default.
• W2955334881 hasRelatedWork W2300929849 @default.
• W2955334881 hasRelatedWork W2407413178 @default.
• W2955334881 hasRelatedWork W2721585150 @default.
• W2955334881 hasRelatedWork W2755364308 @default.
• W2955334881 hasRelatedWork W2765201040 @default.
• W2955334881 hasRelatedWork W2910090032 @default.
• W2955334881 hasRelatedWork W3030929609 @default.
• W2955334881 hasRelatedWork W3196960728 @default.
• W2955334881 hasRelatedWork W4311581284 @default.
• W2955334881 hasVolume "30" @default.
• W2955334881 isParatext "false" @default.
• W2955334881 isRetracted "false" @default.
• W2955334881 magId "2955334881" @default.
• W2955334881 workType "article" @default.